2-[(2S)-2,3-dihydroxypropyl]-8-(2-fluoro-4-iodoanilino)pyrido[3,4-d]pyridazin-1-one | 1609550-72-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-[(2S)-2,3-dihydroxypropyl]-8-(2-fluoro-4-iodoanilino)pyrido[3,4-d]pyridazin-1-one
• CAS: 1609550-72-2
• 化学式: C₁₆H₁₄FIN₄O₃
• 分子量: 456.215
• InChiKey: MXABEVYDQHVOES-NSHDSACASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  25
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  98
• 氢给体数：
  3
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  methyl 3-bromo-5-((2-fluorophenyl)amino)-isonicotinate 在 bis-triphenylphosphine-palladium(II) chloride 、 potassium permanganate 、 sodium periodate 、 N-碘代丁二酰亚胺 、 hydrazine hydrate 、 sodium hydride 、 对甲苯磺酸 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 水 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 38.75h， 生成 2-[(2S)-2,3-dihydroxypropyl]-8-(2-fluoro-4-iodoanilino)pyrido[3,4-d]pyridazin-1-one
  参考文献：
  名称：

  Structure-based design and synthesis of bicyclic fused-pyridines as MEK inhibitors

  摘要：

  The MAPK pathway is identified as one of the most important pathways involved in cell proliferation and differentiation. A key kinase in the pathway, the Mitogen-activated protein kinase kinase (MEK) is recognized as a promising target for antitumor drugs. Structure-based design and optimization of known MEK inhibitors resulted in identification of compound 10a as a potent non-ATP competitive MEK inhibitor in both in vitro and in vivo tests. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.03.086

文献信息

• Structure-based design and synthesis of bicyclic fused-pyridines as MEK inhibitors
  作者：Hejun Lu、Wangyang Tu、Hongbo Fei、Guoji Xu、Qiyue Hu、Lei Zhang、Bing Lin、Jijun Yuan、Junzhao Yin、Aishen Gong、Mimi Wan、Dan Wang、Xiaoyan Zhu、Jun Feng、Qian Wang、Piaoyang Sun

  DOI：10.1016/j.bmcl.2014.03.086

  日期：2014.6

  The MAPK pathway is identified as one of the most important pathways involved in cell proliferation and differentiation. A key kinase in the pathway, the Mitogen-activated protein kinase kinase (MEK) is recognized as a promising target for antitumor drugs. Structure-based design and optimization of known MEK inhibitors resulted in identification of compound 10a as a potent non-ATP competitive MEK inhibitor in both in vitro and in vivo tests. (C) 2014 Elsevier Ltd. All rights reserved.